ALS Breakthrough: New Therapy Offers Hope

A new therapy, tofersen, approved in May 2023, is showing promising results for individuals with a rare genetic form of Amyotrophic Lateral Sclerosis (ALS). Amanda Sifford, diagnosed with an inherited form of the disease, experienced a critical decline in lung function but has since shown remarkable improvement after commencing monthly tofersen infusions.

Initially, Sifford's lung capacity was at 48 percent, but after starting tofersen in July 2023, her capacity rose to 63 percent by January 2026. This outcome is significant as ALS typically causes continuous deterioration.

Tofersen targets the SOD1 gene mutation, affecting approximately 2 percent of ALS patients. Studies indicate that the drug can reduce toxic SOD1 protein levels, potentially slowing disease progression. Some patients have experienced improvements in breathing, strength, and overall function.

While the drug is not a universal cure and can have serious side effects like spinal inflammation, it offers a glimmer of hope. Dr. Timothy Miller, a key researcher, stated, "It tells us that A.L.S. is treatable."

Additional research is underway to explore tofersen's efficacy in patients without SOD1 mutations and to determine if it can prevent the disease in carriers who are not yet symptomatic. The high cost of the drug presents a challenge, though assistance programs are available.